Xenon Pharmaceuticals Inc (NASDAQ: XENE) on Tuesday, soared 1.40% from the previous trading day, before settling in for the closing price of $37.84. Within the past 52 weeks, XENE’s price has moved between $26.74 and $46.00.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 35.90% over the last five years. The company achieved an average annual earnings per share of -34.72%. With a float of $74.20 million, this company’s outstanding shares have now reached $76.42 million.
The firm has a total of 327 workers. Let’s measure their productivity. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Xenon Pharmaceuticals Inc (XENE) Insider Activity
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Xenon Pharmaceuticals Inc is 3.05%, while institutional ownership is 97.31%. The most recent insider transaction that took place on Jan 24 ’25, was worth 903,214. In this transaction PRESIDENT & CEO of this company sold 22,468 shares at a rate of $40.20, taking the stock ownership to the 31,302 shares. Before that another transaction happened on Jan 27 ’25, when Company’s PRESIDENT & CEO sold 16,315 for $40.50, making the entire transaction worth $660,806. This insider now owns 31,302 shares in total.
Xenon Pharmaceuticals Inc (XENE) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.98 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -34.72% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -9.49% during the next five years compared to -14.28% drop over the previous five years of trading.
Xenon Pharmaceuticals Inc (NASDAQ: XENE) Trading Performance Indicators
Xenon Pharmaceuticals Inc (XENE) is currently performing well based on its current performance indicators. A quick ratio of 17.85 was reported for the most recent quarter.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.01, a number that is poised to hit -0.91 in the next quarter and is forecasted to reach -4.51 in one year’s time.
Technical Analysis of Xenon Pharmaceuticals Inc (XENE)
Analysing the last 5-days average volume posted by the [Xenon Pharmaceuticals Inc, XENE], we can find that recorded value of 0.64 million was better than the volume posted last year of 0.58 million. As of the previous 9 days, the stock’s Stochastic %D was 90.93%. Additionally, its Average True Range was 1.95.
During the past 100 days, Xenon Pharmaceuticals Inc’s (XENE) raw stochastic average was set at 69.89%, which indicates a significant decrease from 98.39% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 55.00% in the past 14 days, which was higher than the 45.90% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $35.21, while its 200-day Moving Average is $39.36. Now, the first resistance to watch is $38.95. This is followed by the second major resistance level at $39.54. The third major resistance level sits at $40.54. If the price goes on to break the first support level at $37.36, it is likely to go to the next support level at $36.36. Should the price break the second support level, the third support level stands at $35.77.
Xenon Pharmaceuticals Inc (NASDAQ: XENE) Key Stats
Market capitalization of the company is 2.94 billion based on 76,594K outstanding shares. Right now, sales total 0 K and income totals -234,330 K. The company made 0 K in profit during its latest quarter, and -65,690 K in sales during its previous quarter.
